Roughly six in ten patients with localized solid tumors get radiotherapy with curative intent, and many carry bowel or urinary side effects for years afterward. The problem is timing: clinicians cannot tell before the first dose who will tolerate treatment. A 2026 study in Communications Medicine applied longitudinal plasma proteomics to weekly blood from patients with prostate, bladder, or head and neck cancer, charting how radiation reshapes the circulating proteome and whi

Heart failure in type 2 diabetes often arrives with open coronary arteries and a stiff, poorly relaxing left ventricle, and the molecular reasons have stayed murky in actual human myocardium. A new study in Genome Medicine used multi-omics integration to profile left ventricular tissue from people with diabetic cardiomyopathy, set against non-diabetic cardiomyopathy and healthy donor hearts. The team paired RNA sequencing, 4D-DIA proteomics, and full-spectrum metabolite profi

Roughly one in ten people with rheumatoid arthritis develops interstitial lung disease, and once it shows up the median survival sits near 2.6 years. Diagnosis still hinges on a radiologist reading high-resolution CT, a process that misses early fibrosis and disagrees from one reader to the next. A team working across four Chinese hospitals asked whether multi-omics integration could sharpen that call. From 278 rheumatoid arthritis patients they pulled blood transcriptomics,

Two point mutations in the hepatitis B virus core promoter, A1762T/G1764A and G1896A, track with rougher liver disease, yet clinicians have had little serum-level signal to tell one chronic infection from another. A study in iScience ran 108 treatment-naive chronic hepatitis B patients through multi-omics integration, pairing data-independent acquisition serum proteomics with untargeted metabolomics. One pathway kept surfacing across every comparison: cholesterol metabolism.